Document Detail

The evolution or revolution of statin therapy in primary prevention: where do we go from here?
MedLine Citation:
PMID:  23299639     Owner:  NLM     Status:  In-Data-Review    
CHD morbidity and mortality rates have more than halved since their peak in the 1960s and 1970s. This trend is a result of many factors; however, primary prevention provides the bulk of this benefit. Despite this tremendous progress, cardiovascular disease remains the major cause of death and this trend is projected to persist given the continuous growth in those aged 65 years or greater. Although statin therapy has been a main contributor to a primary prevention strategy, there is still controversy about exposing a large healthy population to long-term statin therapy. Advocates contend the mortality benefits from an aggressive statin approach would remove heart disease from its perch as the greatest killer of Americans and stroke mortality would drop from third to fifth place. Those advocating a much more conservative approach contend the data are not available to expose a healthy population to lifelong statin therapy given limited data on mortality, potential adverse events, and considerable costs. Given these opposing views, this summary of the evolution of statin therapy for the primary prevention of cardiovascular disease will review the major factors fueling this debate.
Patricia Rehfield; Colin Kopes-Kerr; Michael Clearfield
Related Documents :
23434039 - Measuring the burden of chronic diseases in korea in 2007.
21551189 - Ibd and arthropathies: a practical approach to its diagnosis and management.
21139299 - Graves' disease associated with infectious mononucleosis due to primary epstein-barr vi...
21390729 - Detection of treponema pallidum, haemophilus ducreyi, and herpes simplex virus by multi...
21396559 - Skin diseases following a christmas tree pattern.
21477849 - Eosinophilic esophagitis: updated consensus recommendations for children and adults.
3370839 - The isolation and identification of indigoid pigments from urine.
11224019 - The adolescent with simple or corrected congenital heart disease.
12447669 - Molecular diagnostics facilitate distinction between lethal and non-lethal subtypes of ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  15     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  298     Citation Subset:  IM    
Touro University College of Osteopathic Medicine, Vallejo, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does the benefit from statin therapy extend beyond 5 years?
Next Document:  Statins and diabetes: the good, the bad, and the unknown.